Topic overview

Start with the big picture

Management depends on the virus and the patient’s clinical context. HAV has no specific antiviral treatment; prevention may involve vaccine or immune globulin. HBV therapy includes high-resistance-barrier agents such as tenofovir or entecavir, with treatment goals and monitoring extending beyond viral suppression. For HCV, direct-acting antivirals target viral proteins, and pangenotypic regimens are a central treatment approach. The topic also introduces peg-interferon-based therapy for HBV and HDV, selected considerations for chronic HEV infection, and important safety issues such as renal monitoring, drug interactions, pregnancy precautions with ribavirin, and HBV reactivation risk during DAA therapy. Prevention differs across viruses, including the absence of vaccines for HCV and HDV.